Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,114.2
-12.0 (-0.38%)

 

  • STI Straits Times Index
    3,114.2
    -12.0 (-0.38%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,571.2
    -3.4 (-0.21%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,719.6
    -128.9 (-0.48%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,938.1
    -39.2 (-1.32%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    22,492.7
    40.8 (0.18%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,191.9
    10.9 (0.18%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,060.7
    -17.2 (-0.83%)
    Index delayed 20 minutes
  • XAO XAO
    6,758.4
    -33.1 (-0.49%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 937.3M
  • Value: 879.2M
  • Rise: 114
  • Fall: 160
  • Unch: 558

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
MDR0.002-
Rex Intl0.093+0.005
ThaiBev0.900+0.025
Genting Sing0.915-0.010
Spackman0.016-
YZJ Shipbldg SGD0.940-0.010
Y Ventures0.112+0.001
AEM1.280+0.020
KLW0.003-
Singapore-eDev0.045-0.002

World Indices

World Indices
Name Last Change
Nasdaq 8,089.5 -67.3
HSI 26,719.6 -128.9
HSCEI 10,540.0 -48.1
Jakarta 6,191.9 +10.9
Nikkei 225 22,492.7 +40.8
SSE Comp 2,938.1 -39.2
Shanghai A 3,078.2 -41.1
Shanghai B 263.8 -3.3
PSE Comp 0.0
KOSPI 2,060.7 -17.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 18 Oct 2019 14:40
Last (SGD): 0.198 Change: -0.001 High: 0.198 Remarks: -
Change (%): -0.50 Low: 0.198
Open 0.198 Yesterday's Close 0.199
Buy Price 0.197 Sell Price 0.199
Buy Volume ('000) 40.2 Sell Volume ('000) 50.0
Cumulative Volume ('000) 98.8 Cumulative Value 19,562
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.01801 Trailing EPS (SGD) e 0.01687 NAV (SGD) b 0.1353
PE a 10.994 Trailing PE f 11.740 Price / NAV b 1.4634
Dividend (SGD) d 0.005492 Cash In Hand (SGD) g 0.0787 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 2.774 Price / Cash In Hand g 2.516 Treasury Shares h -
Beta - 75 Daysi 0.434 R-Squared - 75 Days(%)i 4.99 Market Cap (M) 59.485
Beta - 500 Daysi 0.291 R-Squared - 500 Days (%)i 0.84 Enterprise Value (M) 39.851
Piotroski F Score - Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 32.0778 6-Month VWAP 0.207 Free Float (%) 20.1
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 14 Aug 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 59.485 10.994 11.740 1.4634 2.774
Industry Medical & Biotechnology SGX 991.522 23.243 26.445 1.4277 1.820
Pharmaceuticals: Major SGX 39.950 10.330 22.350 1.1829 2.065
Local Peer Star Pharm^ SGX 20.414 8.781 - 0.7585 -
Global Peer JOHNSON & JOHNSON NYSE 337,022.009 22.032 19.559 - 2.796
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 219,578.774 17.372 19.232 4.2698 1.939
Global Peer MERCK & CO INC NYSE 216,812.978 34.857 23.159 7.8456 2.380
Global Peer PFIZER INC NYSE 201,662.083 18.083 15.943 3.3864 3.912
Global Peer SANOFI SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 115,691.401 22.705 28.127 1.8028 2.488
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 115,105.667 53.504 52.662 8.4962 3.016
Global Peer ABBVIE INC NYSE 113,044.581 19.983 27.639 -13.1969 5.167
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 106,085.131 21.960 18.511 23.0640 4.784
Global Peer ELI LILLY AND COMPANY NYSE 104,884.641 32.452 25.195 37.7209 2.268
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 97,821.651 15.999 17.036 12.0772 2.165
Other Global Peers BRISTOL-MYERS SQUIBB CO (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), HANSOH PHARMA (HKEx), WUXI APPTEC (HKEx), CHINARES PHARMA (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), INNOVENT BIO-B (HKEx), ALLAKOS INC (NASDAQ), HENLIUS-B (HKEx), CMS (HKEx), JUNSHI BIO-B (HKEx), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), RA PHARMACEUTICALS INC (NASDAQ), CHINAGRANDPHARM (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), TRICIDA INC (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), CSTONE PHARMA-B (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), CANSINOBIO-B (HKEx), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), GOSSAMER BIO INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), UNITED LAB (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), ODONATE THERAPEUTICS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), HUA MEDICINE-B (HKEx), SPRINGWORKS THERAPEUTICS INC (NASDAQ), DOVA PHARMACEUTICALS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ATHENEX INC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), PETIQ INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), FUSEN PHARM (HKEx), AKERO THERAPEUTICS INC (NASDAQ), AKORN INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), LANNETT CO INC (NYSE), APTORUM GROUP LIMITED (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), IGBB (Bursa), BEYONDSPRING INC (NASDAQ), EVOLUS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), OBSEVA SA (NASDAQ), PROVENTION BIO INC (NASDAQ), DAWNRAYS PHARMA (HKEx), KINIKSA PHARMACEUTICALS LTD (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), FORTY SEVEN INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), MIRUM PHARMACEUTICALS INC (NASDAQ), NC HEALTHCARE (HKEx), SATSUMA PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), VERU INC (NASDAQ), MUSTANG BIO INC (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), CHARMACY PHAR (HKEx), MILLENDO THERAPEUTICS INC (NASDAQ), IMMUNIC INC (NASDAQ), Merck Tbk. (IDX), AVENUE THERAPEUTICS INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), THE FS ALSEC ALPHASECTOR (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), CHECKPOINT THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), KOTRA (Bursa), MEDLAB CLINICAL LIMITED (ASX), NOVAN INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ESSA PHARMA INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), EYENOVIA INC (NASDAQ), NEP INTERLONG (HKEx), PALLA PHARMA LTD (ASX), MOLECULIN BIOTECH INC (NASDAQ), NOVA (Bursa), SPRING BANK PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), BIOHLDG (Bursa), ZOMEDICA PHARMACEUTICALS CORP (NYSE American), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), MMJ GROUP HOLDINGS LTD (ASX), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), NOXOPHARM LTD (ASX), BRICKELL BIOTECH INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), SINOLIFE UTD (HKEx), EXOPHARM LTD (ASX), RECCE PHARMACEUTICALS LTD (ASX), AERPIO PHARMACEUTICALS INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), FARMAFORCE LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), RACE ONCOLOGY LTD (ASX), GENPREX INC (NASDAQ), Merck Sharp Dohme Pharma Tbk. (IDX), NOVUS THERAPEUTICS INC (NASDAQ), SIENNA BIOPHARMACEUTICALS INC (NASDAQ), GEMPHIRE THERAPEUTICS INC (NASDAQ), FIJI KAVA LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.001
-0.50 %
10 Days --0.002
-1.00 %
20 Days --0.002
-1.00 %
Medium Term Return 3 Months --0.022
-10.00 %
6 Months 0.006-0.017
-5.12 %
1 Year 0.006-0.017
-5.12 %
Annualised Return Annualised --
-5.12 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.160 - 0.240 Change From 1 Year Low +0.038 % Change From 1 Year Low (%) +23.75
Change From 1 Year High -0.042 % Change From 1 Year High (%) -17.50
2 Years Range 0.160 - 0.305 Change From 2 Years Low +0.038 % Change From 2 Years Low (%) +23.75
Change From 2 Years High -0.107 % Change From 2 Years High (%) -35.08
5 Years Range 0.160 - 0.305 Change From 5 Years Low +0.038 % Change From 5 Years Low (%) +23.75
Change From 5 Years High -0.107 % Change From 5 Years High (%) -35.08
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) -23.85 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
18 Oct 2019 0.198 0.198 0.198 0.198 98,800 0.1980
17 Oct 2019 0.199 0.199 0.199 0.199 18,000 0.1990
16 Oct 2019 0.199 0.199 0.199 0.199 20,000 0.1990
15 Oct 2019 0.200 0.200 0.199 0.199 71,000 0.1994
14 Oct 2019 0.199 0.199 0.199 0.199 - -
11 Oct 2019 0.199 0.199 0.199 0.199 - -
10 Oct 2019 0.199 0.199 0.199 0.199 - -
09 Oct 2019 0.199 0.199 0.199 0.199 21,400 0.1990
08 Oct 2019 0.205 0.205 0.198 0.199 105,300 0.1993
07 Oct 2019 0.200 0.200 0.200 0.200 - -
04 Oct 2019 0.200 0.200 0.200 0.200 30,000 0.2000
03 Oct 2019 0.199 0.200 0.199 0.200 81,100 0.1996
02 Oct 2019 0.199 0.205 0.199 0.200 36,100 0.2000
01 Oct 2019 0.199 0.199 0.199 0.199 - -
30 Sep 2019 0.199 0.199 0.199 0.199 - -
27 Sep 2019 0.200 0.200 0.199 0.199 2,800 0.1993
26 Sep 2019 0.200 0.200 0.200 0.200 20,000 0.2000
25 Sep 2019 0.200 0.200 0.200 0.200 20,000 0.2000
24 Sep 2019 0.200 0.200 0.200 0.200 - -
23 Sep 2019 0.200 0.200 0.200 0.200 60,000 0.2000
20 Sep 2019 0.200 0.200 0.200 0.200 - -
19 Sep 2019 0.200 0.200 0.200 0.200 17,900 0.2000
Summary
Current 2 Weeks
(07 Oct 2019 to 18 Oct 2019)
0.200 0.205 0.198 0.198 334,500 -
Previous 2 Weeks
(23 Sep 2019 to 04 Oct 2019)
0.200 0.205 0.198 0.200 250,000 -
4 Weeks from
(26 Aug 2019 to 20 Sep 2019)
0.200 0.205 0.198 0.200 676,200 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.